Abstract
Today, tacrolimus represents a cornerstone of immunosuppressive therapy for liver and kidney transplants and remains subject of preclinical and clinical investigations, aiming at the development of long-acting depot formulations for subcutaneous injection.One major challenge arises from establishing in vitro-in vivo correlations due to the absence of meaningful in vitro methods predictive for the in vivo situation, together with a strong impact of multiple kinetic processes on the plasma concentration-time profile. In the present approach, two microsphere formulations were compared with regards to their in vitro release and degradation characteristics. A novel biorelevant medium provided the physiological ion and protein background. Release was measured using the dispersion releaser technology under accelerated conditions. A release of 100% of the drug from the carrier was achieved within 7 days. The capability of the in vitro performance assay was verified by the level A in vitro-in vivo correlation analysis. The contributions of in vitro drug release, drug degradation, diffusion rate and lymphatic transport to the absorption process were quantitatively investigated by means of a mechanistic modelling approach. The degradation rate, together with release and diffusion characteristics provides an estimate of the bioavailability and therefore can be a guide to future formulation development.
| Original language | English |
|---|---|
| Pages (from-to) | 372-384 |
| Number of pages | 13 |
| Journal | Journal of Controlled Release |
| Volume | 329 |
| DOIs | |
| Publication status | Published - 10 Jan 2021 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 Elsevier B.V.
Fingerprint
Dive into the research topics of 'Predicting drug release and degradation kinetics of long-acting microsphere formulations of tacrolimus for subcutaneous injection'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver